Medicare's harder problem isn't the negotiated price - it's getting it to the counter

Getting a lower negotiated price is the visible half of Medicare drug-price negotiation; the invisible half is making that price actually reach the person at the pharmacy, and that is what CMS put out for comment this summer [s1]. The draft guidance covers "manufacturer effectuation" of the maximum fair price in 2028, and it confirms that the discount is delivered not as a lower price on the shelf but as a refund the drug company owes back after the sale, due within 14 calendar days [s1][s2].

What was open for comment

The Centers for Medicare & Medicaid Services published a notice (CMS-4219-N) on 20 July 2026 opening comment, through 18 September 2026, on draft guidance for how manufacturers must effectuate the maximum fair price (MFP) in 2028 [s1]. Negotiation itself was created by sections 11001 and 11002 of the Inflation Reduction Act of 2022, signed on 16 August 2022, and is codified at sections 1191 through 1198 of the Social Security Act [s1]. Those sections set the price. The effectuation guidance answers a separate, more operational question: once a drug has an MFP, how does the discount physically move through the supply chain to the pharmacy that dispensed it?

This is not an academic distinction. A pharmacy still buys the drug from a wholesaler at close to the ordinary list price, then dispenses it to a Medicare beneficiary at the MFP. Unless something reimburses the pharmacy for the gap, the pharmacy is out of pocket on every negotiated prescription it fills.

The Medicare Transaction Facilitator

CMS's answer is a system called the Medicare Transaction Facilitator (MTF), built in two parts in the effectuation guidance already in force for 2026 and 2027 and carried forward into the 2028 draft [s2]. An MTF Data Module collects claim-level data on each dispensed selected drug; an MTF Payment Module routes the manufacturer's payment to the dispensing entity [s2]. Under the guidance, a manufacturer must make an amount available that provides access to the MFP within 14 calendar days of when the MTF transmits the relevant claim data — the "prompt MFP payment window" [s2].

The design is retrospective by construction: the pharmacy fronts the discount, and the manufacturer pays it back afterward through the MTF. CMS acknowledged this creates a cash-flow problem for smaller dispensers, and the guidance says pharmacies will be asked, when they enrol in the Data Module, to self-identify whether they anticipate "material cashflow concerns" from waiting on those retrospective refunds [s2]. To standardise what a pharmacy is owed, CMS specified that the MTF calculates a Standard Default Refund Amount using wholesale acquisition cost as the reference [s2].

Why 2028 is the guidance that matters now

The program is no longer hypothetical. The first negotiated prices took effect in 2026 [s2], and CMS has already announced the second cycle: 15 drugs covered under Medicare Part D, with maximum fair prices taking effect on 1 January 2027 [s3]. Each new applicability year needs its own effectuation rules confirmed in advance so manufacturers, plans, and pharmacies can build the plumbing before the prices switch on. The 2028 draft is that step for the cycle after next. For how the negotiated prices themselves were set and which drugs they covered, see what the first round of negotiation actually changed; for the separate proposal to lock the whole program into formal regulation, see CMS's permanent-framework rule.

The evidence question the mechanism raises

The open empirical question is whether a retrospective-refund design delivers the intended saving to the patient without introducing friction that eats into it. On the plus side, routing payment through a single facilitator with a defined 14-day deadline is meant to make the flow predictable and auditable rather than leaving pharmacies to chase each manufacturer [s2]. On the other side, any system in which the discount arrives after the sale shifts working-capital risk onto the dispenser first — which is why CMS built in the cash-flow self-identification step at all [s2]. Whether that is enough to keep independent and rural pharmacies whole is not something the guidance can answer; it is something only the data from the first effectuation years will show.

None of this changes what a beneficiary pays at the register, which is governed by their plan's cost-sharing rules, not by the MFP directly. The negotiated price lowers what the plan and the program pay for the drug; how much of that reaches an individual depends on separate features of the benefit, including the Part D out-of-pocket cap and the role of pharmacy benefit managers in setting formularies.

What to watch

Whether CMS finalises the 2028 effectuation rules as drafted or adjusts the 14-day window and the cash-flow provisions in response to comments; whether the Payment Module functions at scale once dozens rather than a handful of drugs carry maximum fair prices; and whether pharmacies that flagged material cash-flow concerns get any accommodation, or absorb the timing gap themselves.